Interestingly, such epigenetic silencing of RASSF6 and RASSF10 appeared to be extremely frequent in childhood leukemia, and were reversed by treatment with the hypomethylating drug decitabine, underlying the potential of epigenetic drugs in the treatment of HMs. This evidence concerns the gene RASSF10 and leukemia.